Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9058) 9058
Newsletter (492) 492
Newspaper Article (167) 167
Book Chapter (136) 136
Magazine Article (86) 86
Transcript (26) 26
Dissertation (14) 14
Conference Proceeding (7) 7
Book / eBook (4) 4
Reference (3) 3
Trade Publication Article (3) 3
Web Resource (2) 2
Publication (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7096) 7096
science & technology (6585) 6585
life sciences & biomedicine (6171) 6171
male (3568) 3568
protease inhibitors (3323) 3323
hiv infections - drug therapy (3199) 3199
female (3151) 3151
adult (2671) 2671
proteases (2638) 2638
hiv protease inhibitors - adverse effects (2285) 2285
biological and medical sciences (2271) 2271
medical sciences (2143) 2143
middle aged (2135) 2135
infectious diseases (2059) 2059
hiv protease inhibitors - therapeutic use (1718) 1718
hiv (1668) 1668
animals (1649) 1649
drug therapy, combination (1489) 1489
pharmacology & pharmacy (1457) 1457
antiviral agents (1419) 1419
pharmacology. drug treatments (1394) 1394
drug therapy (1335) 1335
aids/hiv (1142) 1142
health aspects (1118) 1118
immunology (1112) 1112
protease inhibitors - therapeutic use (1094) 1094
treatment outcome (1062) 1062
research (1015) 1015
anti-hiv agents - therapeutic use (979) 979
anti-hiv agents - adverse effects (959) 959
hiv protease inhibitors - administration & dosage (910) 910
human immunodeficiency virus--hiv (884) 884
viral diseases (879) 879
risk factors (877) 877
aged (864) 864
hiv infection (811) 811
care and treatment (798) 798
human viral diseases (785) 785
analysis (782) 782
drug interactions (758) 758
antibiotics. antiinfectious agents. antiparasitic agents (745) 745
virology (745) 745
protease inhibitors - adverse effects (739) 739
highly active antiretroviral therapy (737) 737
viral load (731) 731
ritonavir - adverse effects (729) 729
microbiology (726) 726
hiv infections - complications (713) 713
antiretroviral drugs (709) 709
abridged index medicus (706) 706
proteins (700) 700
viral diseases of the lymphoid tissue and the blood. aids (662) 662
ritonavir - therapeutic use (629) 629
reverse transcriptase inhibitors - therapeutic use (615) 615
cd4 lymphocyte count (601) 601
hepatitis c (597) 597
hiv infections - virology (589) 589
protease inhibitors - pharmacology (586) 586
hepatitis c virus (582) 582
aids (578) 578
antiviral agents - therapeutic use (574) 574
ritonavir (535) 535
reverse transcriptase inhibitors - adverse effects (532) 532
antiretroviral therapy (529) 529
adolescent (528) 528
mice (522) 522
ritonavir - administration & dosage (520) 520
hiv-1 (509) 509
medicine & public health (502) 502
physiological aspects (499) 499
clinical trials (479) 479
antiretroviral therapy, highly active - adverse effects (476) 476
protease (473) 473
human immunodeficiency virus (470) 470
medical research (467) 467
hiv-1 - drug effects (466) 466
hepatitis c, chronic - drug therapy (463) 463
protease inhibitor (459) 459
hiv patients (455) 455
medicine (454) 454
hiv protease inhibitors - pharmacokinetics (453) 453
general & internal medicine (450) 450
proteinase inhibitors (448) 448
anti-hiv agents - administration & dosage (445) 445
biochemistry & molecular biology (443) 443
dosage and administration (442) 442
antiretroviral therapy, highly active (441) 441
lopinavir (434) 434
research article (434) 434
medicine, general & internal (424) 424
drug administration schedule (417) 417
prospective studies (406) 406
patients (405) 405
enzymes (404) 404
time factors (403) 403
oncology (401) 401
gastroenterology & hepatology (394) 394
young adult (394) 394
clinical trials as topic (392) 392
dose-response relationship, drug (390) 390
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9613) 9613
Spanish (133) 133
German (112) 112
French (77) 77
Japanese (49) 49
Portuguese (41) 41
Russian (27) 27
Italian (16) 16
Danish (11) 11
Dutch (11) 11
Polish (7) 7
Chinese (5) 5
Swedish (4) 4
Hungarian (3) 3
Hebrew (2) 2
Norwegian (2) 2
Persian (2) 2
Turkish (2) 2
Croatian (1) 1
Czech (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
by Drucker, Daniel J and Nauck, Michael A
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Changes in bone mineral density after initiation of antiretroviral treatment with Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir
by Brown, Todd T and Moser, Carlee and Currier, Judith S and Ribaudo, Heather J and Rothenberg, Jennifer and Kelesidis, Theodoros and Yang, Otto and Dubé, Michael P and Murphy, Robert L and Stein, James H and Mccomsey, Grace A
The Journal of infectious diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Index Medicus | Abridged Index Medicus | Major and Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
by Chayama, Kazuaki and Takahashi, Shoichi and Toyota, Joji and Karino, Yoshiyasu and Ikeda, Kenji and Ishikawa, Hiroki and Watanabe, Hideaki and McPhee, Fiona and Hughes, Eric and Kumada, Hiromitsu
Hepatology (Baltimore, Md.), ISSN 0270-9139, 03/2012, Volume 55, Issue 3, pp. 742 - 748
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Antiviral agents | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antibiotics. Antiinfectious agents. Antiparasitic agents | Recombinant Proteins - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Diarrhea - epidemiology | Male | Diarrhea - chemically induced | Polyethylene Glycols - therapeutic use | Incidence | Hepatitis C - ethnology | Treatment Failure | Protease Inhibitors - adverse effects | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Headache - chemically induced | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Japan | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Headache - epidemiology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Aged | Viral Nonstructural Proteins - antagonists & inhibitors | Proteins | Hepatitis | Genotype & phenotype | Interferon | Infections | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
by Arribas, Jose R, Dr and Pialoux, Gilles, Prof and Gathe, Joseph, MD and Di Perri, Giovanni, Prof and Reynes, Jacques, Prof and Tebas, Pablo, MD and Nguyen, Thai, MD and Ebrahimi, Ramin, MS and White, Kirsten, PhD and Piontkowsky, David, MD
The Lancet infectious diseases, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Middle Aged | Male | Thiazoles - therapeutic use | Thiazoles - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - adverse effects | Quinolones - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Protease Inhibitors - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Organophosphonates - adverse effects | Drug Therapy, Combination - methods | HIV | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Adults | Protease inhibitors | Proteases | Antiretroviral drugs | Patient satisfaction | Drug therapy | Laboratories | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Ombitasvir/paritaprevir/ritonavir & dasabuvir +/- ribavirin following protease inhibitors failure-a prospective multi-centre trial
by Deutsch, Liat and Houri, Inbal and Ben-Ari, Ziv and Shlomai, Amir and Veitsman, Ella and Cohen-Ezra, Oranit and Issachar, Assaf and Mor, Orna and Gozlan, Yael and Bruck, Rafael and Menachem, Yoram and Zelber-Sagi, Shira and Katchman, Helena and Shibolet, Oren
BMC infectious diseases, ISSN 1471-2334, 04/2020, Volume 20, Issue 1, pp. 264 - 264
Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Anilides - therapeutic use | Prospective Studies | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Middle Aged | Male | Ritonavir - adverse effects | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical research | Antiviral agents | Liver diseases | Liver | Biological products industry | Biological response modifiers | Infection | Protease inhibitors | Proteases | Medicine, Experimental | Product development | Drug therapy | Hepatitis C virus | Health aspects | Ritonavir | Health services | Chronic infection | Viruses | Hepatocellular carcinoma | Infections | Ribavirin | Genotype & phenotype | Hepatitis | Protease | Drug dosages | Failure | Genotypes | Medical treatment | Proteinase inhibitors | Patients | Ankle | Side effects | Hypotheses | Fibrosis | Interferon | Hepatitis C | Index Medicus | Direct acting anti-viral agents | HCV | AbbVie 3D | Protease inhibitors failure
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
by Zeuzem, Stefan and Asselah, Tarik and Angus, Peter and Zarski, Jean–Pierre and Larrey, Dominique and Müllhaupt, Beat and Gane, Ed and Schuchmann, Marcus and Lohse, Ansgar and Pol, Stanislas and Bronowicki, Jean–Pierre and Roberts, Stuart and Arasteh, Keikawus and Zoulim, Fabien and Heim, Markus and Stern, Jerry O and Kukolj, George and Nehmiz, Gerhard and Haefner, Carla and Boecher, Wulf Otto
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2011, Volume 141, Issue 6, pp. 2047 - 2055
Gastroenterology and Hepatology | Drug | Peginterferon-Free | Direct-Acting Antivirals | Clinical Trial | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Acrylates - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Thiazoles - therapeutic use | Oligopeptides - adverse effects | Thiazoles - adverse effects | Viral Load | Acrylates - adverse effects | Oligopeptides - therapeutic use | Protease Inhibitors - adverse effects | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | RNA-Dependent RNA Polymerase - antagonists & inhibitors | Ribavirin - adverse effects | Antiviral Agents - adverse effects | RNA, Viral - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Complications and side effects | Antiviral agents | Care and treatment | Protease inhibitors | Proteases | Universities and colleges | Hepatitis C | Hepatitis C virus | Ribavirin | Anti-HIV agents | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text New protease inhibitors for the treatment of chronic hepatitis C: A cost-effectiveness analysis
by Liu, Shan and Cipriano, Lauren E and Holodniy, Mark and Owens, Douglas K and Goldhaber-Fiebert, Jeremy D
Annals of internal medicine, ISSN 0003-4819, 2012, Volume 156, Issue 4, pp. 279 - 290
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Markov Chains | Ribavirin - economics | Humans | Male | Liver Cirrhosis - economics | Liver Neoplasms - etiology | Interleukins - genetics | Protease Inhibitors - adverse effects | Female | Carcinoma, Hepatocellular - etiology | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Quality-Adjusted Life Years | Liver Cirrhosis - drug therapy | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Risk Factors | Decision Support Techniques | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Genotype | Treatment Outcome | Protease Inhibitors - economics | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - economics | Disease Progression | Medication Adherence | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Cost-Benefit Analysis | Interferon-alpha - adverse effects | Antiviral Agents - economics | Hepatitis C, Chronic - genetics | Research | Protease inhibitors | Hepatitis C | Drug therapy | Health aspects | Clinical trials | Genotype & phenotype | Hepatitis | Medical treatment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on Bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system
by Dou, Q. Ping and Zonder, Jeffrey A
Current cancer drug targets, ISSN 1568-0096, 2014, Volume 14, Issue 6, pp. 517 - 536
Bortezomib | Proteasome inhibitor | Multiple myeloma | Carfilzomib | Combination therapy | Immunoproteasomes | Resistance to proteasome inhibitors | Ubiquitin-proteasome pathway | Life Sciences & Biomedicine | Oncology | Science & Technology | Ubiquitin-Specific Proteases - antagonists & inhibitors | Humans | Ubiquitin-Protein Ligases - metabolism | Boronic Acids - adverse effects | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Molecular Targeted Therapy | Proteasome Inhibitors - adverse effects | Proteasome Inhibitors - therapeutic use | Proteolysis - drug effects | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Animals | Ubiquitin-Protein Ligase Complexes - metabolism | Ubiquitination - drug effects | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Drug Design | Pyrazines - adverse effects | Proteasome Endopeptidase Complex - metabolism | Multiple Myeloma - enzymology | Ubiquitin-Specific Proteases - metabolism
Journal Article
Details down arrow